Effects of Reduced Nicotine Content Cigarettes on Fractional Exhaled Nitric Oxide and Self-Reported Respiratory Health Outcomes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 22 01 2021
accepted: 12 07 2021
pubmed: 14 7 2021
medline: 6 1 2022
entrez: 13 7 2021
Statut: ppublish

Résumé

This study examined whether exposure to reduced-nicotine-content cigarettes (RNCCs) for 12 weeks alters respiratory health using Fractional Exhaled Nitric Oxide (FeNO), a validated biomarker of respiratory epithelial health, and the Respiratory Health Questionnaire (RHQ), a subject-rated questionnaire on respiratory symptoms. Participants were 747 adult daily smokers enrolled in three double-blind, randomized clinical trials evaluating effects of cigarette nicotine content (0.4, 2.4, 15.8 mg nicotine/g tobacco) in people with affective disorders, opioid use disorder (OUD), or socioeconomic disadvantage. FeNO levels and RHQ ratings were collected at baseline and Weeks 6 and 12 following randomization. Multiple regression was used to assess associations of FeNO and RHQ with smoking characteristics. Mixed-model repeated-measures ANOVA was used to evaluate the effects of nicotine content on FeNO and RHQ outcomes over the 12-week study period. FeNO levels but not RHQ ratings varied inversely with smoking characteristics at baseline (Ps < 0.0001) in smokers with affective disorders and socioeconomic disadvantage but less so in those with OUD. Participants with affective disorders and socioeconomic disadvantage, but not those with OUD, who were assigned to RNCCs had higher FeNO levels at Week 12 than those assigned to the 15.8 mg/g dose [F(2,423) = 4.51, p = .01, Cohen's d = 0.21]. No significant dose-related changes in RHQ scores were identified. Use of RNCCs across a 12-week period attenuates smoking-related reductions in FeNO levels in smokers with affective disorders and socioeconomic disadvantage although not those with OUD. FeNO changes were not accompanied by changes in respiratory-health ratings. Inclusion and exclusion criteria for the sample and experimental manipulation of the nicotine content of assigned cigarettes are registered: NCT02232737, NCT02250664, NCT02250534. The FeNO measure reported in this manuscript is an exploratory outcome that was not registered. Should a reduced nicotine content standard be implemented; these results suggest that reduced nicotine content in cigarettes will not exacerbate and instead may attenuate smoking-related decreases in FeNO. This is significant as NO is an important component in maintaining a healthy respiratory system and necessary to defend against infection. Furthermore, the results of the current study demonstrate that the adoption of the reduced nicotine content standard may result in beneficial impacts on respiratory epithelial health among vulnerable populations that are disproportionally affected by the adverse health outcomes precipitated by combustible tobacco use.

Identifiants

pubmed: 34255068
pii: 6320035
doi: 10.1093/ntr/ntab145
pmc: PMC8826384
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Banques de données

ClinicalTrials.gov
['NCT02250664', 'NCT02232737', 'NCT02250534']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-140

Subventions

Organisme : NIDA NIH HHS
ID : K12 DA043490
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103644
Pays : United States
Organisme : NIDA NIH HHS
ID : U54 DA036114
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Am J Respir Crit Care Med. 1995 Aug;152(2):609-12
pubmed: 7543345
N Engl J Med. 2015 Oct;373(14):1340-9
pubmed: 26422724
Clin Respir J. 2013 Apr;7(2):113-20
pubmed: 22789005
Eur J Clin Invest. 2016 Aug;46(8):698-706
pubmed: 27322745
JAMA Psychiatry. 2017 Oct 1;74(10):1056-1064
pubmed: 28832876
Chest. 1997 Aug;112(2):313-8
pubmed: 9266863
J Allergy Clin Immunol. 2005 Jul;116(1):88-93
pubmed: 15990779
Inhal Toxicol. 2016 Dec;28(14):724-730
pubmed: 27973944
Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S38-S45
pubmed: 31867650
N Engl J Med. 1994 Jul 14;331(2):123-5
pubmed: 7818638
Chest. 2005 Oct;128(4):2528-37
pubmed: 16236919
JAMA Netw Open. 2020 Oct 1;3(10):e2019311
pubmed: 33079196
Liver Transpl. 2010 Jul;16(7):870-3
pubmed: 20583080
BMC Pulm Med. 2017 Aug 25;17(1):118
pubmed: 28841881
Toxicology. 2009 Feb 4;256(1-2):83-91
pubmed: 19070643
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
Clin Rev Allergy Immunol. 2014 Feb;46(1):54-64
pubmed: 23636734
Respirology. 2013 Feb;18(2):255-62
pubmed: 23066838

Auteurs

Anthony C Oliver (AC)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Michael DeSarno (M)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Medical Biostatistics, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Charles G Irvin (CG)

Vermont Lung Center, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

David Kaminsky (D)

Vermont Lung Center, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Jennifer W Tidey (JW)

Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA.

Stacey C Sigmon (SC)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychological Science, University of Vermont, Burlington, VT, USA.

Sarah H Heil (SH)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychological Science, University of Vermont, Burlington, VT, USA.

Diann E Gaalema (DE)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychological Science, University of Vermont, Burlington, VT, USA.

Dustin Lee (D)

Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Janice Y Bunn (JY)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Medical Biostatistics, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Danielle R Davis (DR)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.

Joanna M Streck (JM)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Thomas Gallagher (T)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Stephen T Higgins (ST)

Vermont Center on Behavior and Health, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychiatry, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Department of Psychological Science, University of Vermont, Burlington, VT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH